Jan Versijpt, MD, PhD Neurologist, UZ Brussel, Belgium.
Migraine management is not fully meeting the needs of patients and clinicians in three important areas: the role of monoclonal antibodies targeting CGRP, understanding the clinical role of neuromodulation and the development of biomarkers for migraine.

References

1. Alex A, Vaughn C, Rayhill M. Safety and tolerability of 3 CGRP monoclonal antibodies in practice: a retrospective cohort study. Headache. 2020;60:2454-2462.
2. Diener HC, Goadsby PJ, Ashina M, et al. Non-invasive vagus nerve stimulation (nVNS) for the preventive treatment of episodic migraine: the multicentre, double-blind, randomised, sham-controlled PREMIUM trial. Cephalalgia. 2019;39:1475-1487.
3. Durham P, Papapetropoulos S. Biomarkers associated with migraine and their potential role in migraine management. Headache. 2013;53:1262-77.
4. Cernuda-Morollón E, Larrosa D, Ramón C, et al. Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology. 2013;81:1191-6.
5. Frisoni GB, Boccardi M, Barkhof F, et al. Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. Lancet Neurol. 2017;16:661-676.
6. Viana M, Sances G, Terrazzino S, et al. Predicting the response to a triptan in migraine using deep attack phenotyping: a feasibility study. Cephalalgia. 2020:333102420959786. doi: 10.1177/0333102420959786.